

**Online Table 1: Tumor laterality, international classification of intraocular retinoblastoma group, SOAIC agents, and adjunctive therapies in aggregate population**

	International Classification of Intraocular Retinoblastoma Group B Eyes (Fraction of Total Eyes)		International Classification of Intraocular Retinoblastoma Group C Eyes (Fraction of Total Eyes)		International Classification of Intraocular Retinoblastoma Group D Eyes (Fraction of Total Eyes)		International Classification of Intraocular Retinoblastoma Group E Eyes (Fraction of Total Eyes)		Single-Agent, Topotecan (Fraction of Total Eyes)		Triple-Agent Melphalan (Fraction of Total Eyes)			
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)		
Aggregate study population	4	(0.19)	3	(0.14)	12	(0.57)	2	(0.09)	14	(0.67)	2	(0.09)	5	(0.24)
n = 21 eyes														
n = 20 patients														
Eyes treated with IAV	4	(0.27)	1	(0.07)	8	(0.53)	2	(0.13)	10	(0.67)	0	(0)	5	(0.33)
Eyes treated with INA	0	(0)	2	(0.33)	4	(0.67)	0	(0)	4	(0.67)	2	(0.33)	0	(0)
Eyes treated with adjunctive ECBO	4	(0.28)	2	(0.14)	8	(0.57)	0	(0)	11	(0.78)	2	(0.14)	1	(0.07)
Eye status according to DTR	0	(0)	1	(0.14)	4	(0.57)	2	(0.28)	3	(0.43)	0	(0)	4	(0.57)
+ (n = 15 eyes)	3	(0.21)	2	(0.14)	9	(0.64)	0	(0)	10	(0.71)	1	(0.07)	3	(0.21)
- (n = 6 eyes)	1	(0.14)	1	(0.14)	3	(0.43)	2	(0.28)	4	(0.57)	1	(0.14)	2	(0.28)
Satisfactory (n = 15 eyes)	4	(0.27)	1	(0.07)	9	(0.60)	1	(0.07)	12	(0.80)	0	(0)	3	(0.20)
Poor (n = 6 eyes)	0	(0)	2	(0.33)	3	(0.50)	1	(0.17)	2	(0.33)	2	(0.33)	2	(0.33)

**Note:**—+ indicates receiving; —, not receiving.

**Online Table 2: Correlation of QTR with therapeutic adjuncts**

	SOAIC Treatments with IAV Total <i>n</i> = 15 (Proportion of Total)	SOAIC Treatments without IAV Total <i>n</i> = 6 (Proportion of Total)	SOAIC Treatments with INA Total <i>n</i> = 14 (Proportion of Total)	SOAIC Treatments without INA Total <i>n</i> = 7 (Proportion of Total)	SOAIC Treatments with ECBO Total <i>n</i> = 14 (Proportion of Total)	SOAIC Treatments without ECBO Total <i>n</i> = 7 (Proportion of Total)
Aggregate study population, ( <i>n</i> = 21) Average QTR [SD]	63.0 [SD, 19.6]	49.2 [SD, 28.7]	60.3 [SD, 22.8]	56.4 [SD, 24.1]	64.2 [SD, 19.9]	48.6 [SD, 25.9]
SOAIC with single-agent melphalan at any dose ( <i>n</i> = 14) Average QTR [SD]	70.0 (SD, 14.1)	58.7 [SD, 30.6]	67.7 [SD, 19.3]	63.3 [SD, 24.7]	70.0 [SD, 19.4]	58.7 [SD, 20.1]
SOAIC with single-agent melphalan at doses of <5 mg ( <i>n</i> = 12) Average QTR [SD]	70.0 [SD, 14]	32.5 [SD, 3.5]	63.9 [SD, 19.2]	63.3 [SD, 24.7]	67.8 [SD, 19.2]	51.7 [SD, 17.5]

**Online Table 3: Correlation of DTR with therapeutic adjuncts**

	SOAIC Treatments with IAV Total <i>n</i> = 15 (Proportion of Total)	SOAIC Treatments without IAV Total <i>n</i> = 6 (Proportion of Total)	SOAIC Treatments with INA Total <i>n</i> = 14 (Proportion of Total)	SOAIC Treatments without INA Total <i>n</i> = 7 (Proportion of Total)	SOAIC Treatments with ECBO Total <i>n</i> = 14 (Proportion of Total)	SOAIC Treatments without ECBO Total <i>n</i> = 7 (Proportion of Total)
Aggregate study population ( <i>n</i> = 21) Poor DTR <i>n</i> = 6 (QTR <50%) Satisfactory DTR <i>n</i> = 15 (QTR ≥ 50%)	2 (0.13) 13 (0.87)	4 (0.67) 2 (0.33)	4 (0.29) 10 (0.71)	2 (0.29) 5 (0.71)	3 (0.21) 11 (0.79)	3 (0.43) 4 (0.57)
SOAIC with single-agent melphalan at any dose ( <i>n</i> = 14) Poor DTR <i>n</i> = 2 (QTR < 50%) Satisfactory DTR <i>n</i> = 12 (QTR ≥ 50%)	0 (0) 10 (1.00)	2 (0.50) 2 (0.50)	1 (0.09) 10 (0.91)	1 (0.33) 2 (0.67)	1 (0.10) 9 (0.90)	1 (0.25) 3 (0.75)
SOAIC with single-agent melphalan at doses of <5 mg ( <i>n</i> = 12) Poor DTR <i>n</i> = 2 (QTR < 5-0%) Satisfactory DTR <i>n</i> = 10 (QTR ≥ 50%)	0 (0) 10 (1.0)	2 (1.0) 0 (0)	1 (0.11) 8 (0.89)	1 (0.33) 2 (0.67)	1 (0.11) 8 (0.89)	1 (0.33) 2 (0.67)

**Online Table 4: Correlation of CIT and FT with therapeutic adjuncts**

	SOAIC Treatments with IAV Total <i>n</i> = 15 (Proportion of Total)	SOAIC Treatments without IAV Total <i>n</i> = 6 (Proportion of Total)	SOAIC Treatments with INA Total <i>n</i> = 14 (Proportion of Total)	SOAIC Treatments without INA Total <i>n</i> = 7 (Proportion of Total)	SOAIC Treatments with ECBO Total <i>n</i> = 14 (Proportion of Total)	SOAIC Treatments without ECBO Total <i>n</i> = 7 (Proportion of Total)
Aggregate study population ( <i>n</i> = 21) Average CIT [SD] Average FT [SD]	30.7 [SD, 11.6] 32.0 [SD, 15.8]	32.2 [SD, 6.0] 23.2 [SD, 8.9]	31.1 [SD, 12.0] 34.6 [SD, 15.3]	31.1 [SD, 5.8] 19.1 [SD, 3.5]	32.7 [SD, 10.5] 33.4 [SD, 15.3]	27.9 [SD, 9.4] 21.7 [SD, 9.7]
SOAIC with single- agent melphalan at any dose ( <i>n</i> = 14) Average CIT [SD] Average FT [SD]	28.8 [SD, 13.1] 37.2 [SD, 16.9]	33.7 [SD, 7.0] 23.0 [SD, 10.9]	30.5 [SD, 13.2] 37.2 [SD, 16.3]	29.0 [SD, 1.0] 18.3 [SD, 1.5]	32.9 [SD, 12.1] 36.7 [SD, 17.0]	23.5 [SD, 7.9] 24.2 [SD, 12.3]

**Online Table 5: Correlation of epoch with QTR, CIT, FT, and dichotomous therapeutic response**

	Aggregate Study Population		SOAIC with Melphalan Group	
	Early-Epoch SOAIC Treatments Total <i>n</i> = 11 (Proportion of Total)	Late-Epoch SOAIC Treatments Total <i>n</i> = 10 (Proportion of Total)	Early-Epoch SOAIC Treatments Total <i>n</i> = 7 (Proportion of Total)	Late-Epoch SOAIC Treatments Total <i>n</i> = 7 (Proportion of Total)
Poor response (QTR < 50%)	4 (0.36)	2 (0.20)	2 (0.29)	0 (0)
Satisfactory response (QTR ≥ 50%)	7 (0.64)	8 (0.80)	5 (0.71)	7 (1.00)
Average QTR [SD]	57.2 [SD, 25.5]	60.5 [SD, 20.5]	65.0 [SD, 26.4]	68.6 [SD, 11.0]
Average CIT [SD]	32.4 [SD, 6.3]	29.6 [SD, 13.4]	32.0 [SD, 6.3]	28.4 [SD, 15.7]
Average FT [SD]	25.7 [SD, 8.2]	33.6 [SD, 19.0]	27.6 [9.7]	38.7 [SD, 20.4]

**Online Table 6: Correlation of CIT and FT intervals with QTR, epoch, and dichotomous therapeutic response in aggregate population**

	Satisfactory Response QTR ≥ 50% Total <i>n</i> = 15 (Proportion of Total)	Poor Response QTR < 50% Total <i>n</i> = 6 (Proportion of Total)	Early-Epoch Total <i>n</i> = 11 (Proportion of Total)	Late-Epoch Total <i>n</i> = 10 (Proportion of Total)	Average QTR [SD]
Average CIT (min) [SD]	30.2 [SD, 11.3]	31.7 [SD, 7.0]	32.4 [SD, 6.3]	29.6 [SD, 13.4]	NA
Brief infusion time, CIT < 20 min ( <i>n</i> = 2)	2 (1.00)	0 (0)	0 (0)	2 (1.00)	67.5 [SD, 3.5]
Intermediate infusion time CIT = 20–38 min ( <i>n</i> = 15)	11 (0.73)	4 (0.27)	9 (0.60)	6 (0.40)	59.0 [SD, 24.5]
Prolonged infusion time, CIT, ≥ 9 min ( <i>n</i> = 5)	3 (0.60)	2 (0.40)	3 (0.60)	2 (0.40)	44.8 [SD, 9.0]
Average FT (min)	31.9 [SD, 16.1]	23.3 [SD, 7.7]	25.7 [SD, 8.2]	33.6 [SD, 19.0]	NA
Brief fluoroscopy time, <20 min ( <i>n</i> = 5)	2 (0.40)	3 (0.60)	3 (0.60)	2 (0.40)	45.0 [SD, 30.6]
Intermediate fluoroscopy time, 20–35 min ( <i>n</i> = 11)	8 (0.73)	3 (0.27)	7 (0.64)	4 (0.36)	59.5 [SD, 19.0]
Prolonged fluoroscopy time, >35 min ( <i>n</i> = 5)	5 (1.00)	0 (0)	1 (0.20)	4 (0.80)	72.0 [SD, 16.8]

**Note:**—NA indicates not applicable.

**Online Table 7: Procedure-related adverse events**

Adverse Event	Patient Age	IAV Status	INA Status	ECBO Status	Chemotherapy Agents	FT (Min)	CIT (Min)
<b>Ocular adverse events</b>							
Severe diffuse ocular edema requiring oral steroid therapy	12 mo	+	∅	+	Melphalan	41	31
Small retinal hemorrhage involving internal limiting membrane of retina	10 mo	+	+	+	Melphalan	36	14
Small subretinal hemorrhage	2 mo	+	+	+	Triple-agent chemotherapy	41	29
Eyelid edema requiring oral steroid therapy	48 mo	∅	∅	+	Triple-agent chemotherapy	27	13
<b>Neurovascular adverse events</b>							
Focal catheterization-related spasm of ophthalmic artery resulting in transient ophthalmic artery flow reversal, resolved with IAV	7 mo	+	+	+	Melphalan	76	60
Nonflow restrictive spasm in cortical branches of MCA on initial angiography, resolved spontaneously during the procedure; no clinical or brain MR imaging findings on follow-up	8 mo	+	+	+	Melphalan	36	36
<b>Cardiovascular adverse events</b>							
Transient procedure-related hypotension related to verapamil administration resolved with intravenous albumin boluses and calcium gluconate	7 mo	+	+	+	Melphalan	76	60
Perioperative hypotension and anemia requiring intravenous hydration and packed red blood cell transfusion	8 mo	+	+	+	Melphalan	36	36
<b>Respiratory adverse events</b>							
Postextubation laryngospasm requiring reintubation and overnight hospital admission	9 mo	+	+	+	Melphalan	32	28
Intraoperative bronchospasm	10 mo	+	+	∅	Melphalan	36	12
Intraoperative bronchospasm	10 mo	+	+	+	Melphalan	36	14
<b>Access site adverse events</b>							
Self-limited groin hematoma not requiring treatment	36 mo	+	+	+	Melphalan	25	26
Transient thrombosis of left external iliac artery treated with lovenox, without sequelae	10 mo	+	+	+	Triple-agent chemotherapy	41	25

If a therapeutic adjunct (IAV, INA, ECBO) was employed during the index SOAIC corresponding to the listed complication a (+) is indicated in the status column of the corresponding therapeutic adjunct.

If a therapeutic adjunct (IAV, INA, ECBO) was not employed during the index SOAIC corresponding to the listed complication a (∅) is indicated under the status column of the corresponding therapeutic adjunct.